Soluble CD30 in renal transplant recipients : is it a good biomarker to predict rejection ?

Abstract EN

It has been suggested that the serum soluble CD30 (sCD30) level may be a potential marker for the prediction of acute allograft rejection in kidney transplant recipients.

Therefore, its serum concentrations might offer a promising non-invasive tool to recognize patients with an increased risk for developing an acute graft rejection.

We retrospectively correlate pre and post transplant level on post transplant graft survival, incidence of acute rejection and graft function using stored serum samples.

Ninety-nine patients were divided in two separate groups: Group A in whom sample collection was done one day before transplantation and Group B where sample collection was done five days after transplantation.

Younger recipients (aged less than 20 years) had higher sCD30 levels (P= 0.02).

There was neither significant difference in the incidence of acute rejection nor incomplete response rate after anti rejection therapy in relation to pre transplant or post transplant sCD30.

We could not find a significantly inferior graft survival rate in the high sCD30 group.

In conclusion, younger patients had higher sCD30 concentrations however no correlation existed between the serum concentrations and occurrence of rejection episodes or graft survival.